Many studies that followed further demonstrated the anti-tumor activity and promise of 4-1BB agonism, alone or in combination with other therapeutic strategies, in different types of cancer, including lymphoma, hepatocellular carcinoma, and melanoma (58, 59). Here, TNFRSF9 is linked to lymphoma.